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Background: Montelukast (MT) is a leukotriene D4 antagonist. It is an effective and safe 
medicine for the prophylaxis and treatment of chronic asthma. It is also used to prevent acute 
exercise-induced bronchoconstriction and as a symptomatic relief of seasonal allergic rhinitis 
and perennial allergic rhinitis.
Objective: The aim of this study was to evaluate the bioequivalence (BE) of two drug products: 
generic MT 5 mg chewable tablets versus the branded drug Singulair® pediatric 5 mg chewable 
tablets among Mediterranean volunteers.
Methods: An open-label, randomized two-period crossover BE design was conducted in 32 
healthy male volunteers with a 9-day washout period between doses and under fasting condi-
tions. The drug concentrations in plasma were quantified by using a newly developed and fully 
validated liquid chromatography tandem mass spectrometry method, and the pharmacokinetic 
parameters were calculated using a non-compartmental model. The ratio for generic/branded 
tablets using geometric least squares means was calculated for both the MT products.
Results: The relationship between concentration and peak area ratio was found to be linear 
within the range 6.098–365.855 ng/mL. The correlation coefficient (R2) was always greater 
than 0.99 during the course of the validation. Statistical comparison of the main pharmacoki-
netic parameters showed no significant difference between the generic and branded products. 
The point estimates (ratios of geometric means) were 101.2%, 101.6%, and 98.11% for area 
under the curve (AUC)
0llast, AUC0linf , and Cmax, respectively. The 90% confidence intervals 
were within the predefined limits of 80.00%–125.00% as specified by the US Food and Drug 
Administration and European Medicines Agency for BE studies.
Conclusion: Broncast® pediatric chewable tablets (5 mg/tablet) are bioequivalent to Singulair® 
pediatric chewable tablets (5 mg/tablet), with a similar safety profile. This suggests that these 
two formulations can be considered interchangeable in clinical practice.
Keywords: montelukast, bioequivalence, chewable, safety, efficacy
Introduction
Montelukast (MT) is a monosodium salt; its IUPAC chemical name is (R,E)-2-(1-
((1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)
propylthio)methyl)cyclopropyl) acetic acid. The chemical structure of MT is shown 
in Figure 1.
MT is a leukotriene receptor antagonist; it specifically blocks the action of leu-
kotriene D4 on the cysteinyl leukotriene receptor of the lungs and bronchial tubes 
and reduces the bronchoconstriction and also inflammation.1,2 Several clinical studies 
have demonstrated the efficacy of MT in the treatment and prophylaxis of chronic 
mild asthma in patients aged 2 years and older.3–7 It has also proved to be effective 
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in the prevention of exercise-induced asthma in patients 
aged above 6 years.8 Moreover, MT has been indicated in 
the symptomatic relief of seasonal and perennial allergic 
rhinitis.9–11 Bioavailability studies showed that the presence 
of food in the gastrointestinal tract did not affect bioavailabil-
ity when the tablet was administered with a standard meal.11 
Moreover, instructions about the use of the brand granules 
report that they can be mixed with one teaspoonful of cold 
or room temperature baby formula or breast milk or with 
one spoonful of one of the following soft foods: applesauce, 
mashed carrots, rice, or ice cream.12
The oral bioavailability of MS when administered 
as a 10 mg film-coated tablet in adults was found to be 
58%–66%.13 Singulair® was approved by the US Food and 
Drug Administration (FDA) for the treatment of asthma and 
allergic rhinitis in August 2012. It is usually administered 
once daily in a dose of 10 mg or 5 mg per tablet. Other dosage 
forms have been approved by the FDA; these include oral 
granules at a dose of 4 mg and chewable tablets at doses of 
4 mg or 5 mg.14,15 In fact, the FDA has invited pharmaceutical 
manufacturers to develop and produce proper dosage forms, 
especially for pediatric patients. In this context, chewable 
tablets are known to be advantageous over liquid dosage 
forms in many aspects, such as higher palatability, better 
bioavailability, stability, dose precision, portability, and ease 
of administration, especially during traveling.16–18 However, 
many challenges may be encountered during the development 
of chewable tablets, such as the taste and the bioequivalence 
(BE) of the drug when compared with the original brand. In 
fact, unsuitable taste may result in poor patient compliance. 
Chewing the tablet may result in immediate disintegration 
and partial dissolution or degradation of the drug in the 
saliva, and this may affect the amount of drug available for 
absorption. In the current study, the generic MT chewable 
tablet was formulated to be tasty, bioavailable, and as safe as 
the original brand. Accordingly, the objective of this study 
was to investigate the BE of this formulation by comparing 
its pharmacokinetic (PK) parameters with the original brand 
by developing a liquid chromatography–mass spectrometry 
(LC-MS) method for the determination of MT. In addition, 
the safety of the two formulations, on the basis of clinical 
and laboratory observation and documentation of adverse 
events, was also investigated (Figure 1).
Materials and methods
The study was a comparative, randomized, two-period, two-
treatment, two-sequence, single-dose, open-label, crossover 
BE study of generic MT 5 mg chewable tablets versus the 
brand drug Singulair® pediatric 5 mg chewable tablets given 
to healthy subjects under fasting conditions.
Volunteers and clinical protocol
The study was conducted by Arab Pharmaceutical Industry 
Consulting Co. Ltd., Jordan in accordance with the require-
ments of the Declaration of Helsinki19 and under the current 
Good Clinical Practice guidelines20 and the International 
Conference for Harmonization21 guidelines. The study pro-
tocol and the informed consent forms were approved by the 
Institutional Review Board. Owing to methodological and 
ethical difficulties and in order to safeguard the pediatric 
population, FDA and European Medicines Agency (EMA) 
guidelines state that PK studies of drugs intended for use 
in a pediatric population can be carried out on healthy 
adults.22,23
Thirty-two adult male volunteers were recruited to 
participate in the study. The volunteers were aged between 
18 years and 50 years, weighing between 57 kg and 93 kg 
with an average weight of 76 kg. The volunteers were sub-
jected to a full medical and physical examination to confirm 
their health status and were not on any medication during 
the study period. A written informed consent form, which 
explained the nature of the study, was given to the volunteers. 
The volunteers were instructed to abstain from taking drugs 
for 1 month before the study initiation, to abstain from caf-
feine and alcohol-containing beverages for at least 16 hours 
prior to each study drug administration and throughout the 
study period, and to fast for at least 10 hours before drug 
administration.
Figure 1 Chemical structure of montelukast.
??
?
?
??
? ??
Drug Design, Development and Therapy 2015:9 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
5317
Investigation of bioequivalence of montelukast chewable tablets
The study used an open-label, randomized two-period 
crossover design with a 9-day washout period between doses 
in 32 healthy subjects under fasting conditions. The volunteers 
were randomly divided into two groups, each of 16 subjects. 
The first group was given the reference brand and the second 
group was given the test formulation with a crossover after 
the washout period. On the morning of the study, each vol-
unteer gave a blood sample to serve as a blank for the drug 
assay. Each volunteer received an oral dose of the assigned 
formulation given with 240 mL of water in the sitting posi-
tion. During each period, blood samples were taken from 
each volunteer for the calculation of the PK parameters at pre 
and up to 24 hours after drug dosing. Each sample volume 
was 8 mL, 1 hour before dosing, and 8 mL of samples were 
withdrawn at the following time points: 0.50 hour, 1.00 hour, 
1.50 hours, 1.75 hours, 2.00 hours, 2.25 hours, 2.50 hours, 
2.75 hours, 3.00 hours, 3.25 hours, 3.50 hours, 3.75 hours, 
4.00 hours, 5.00 hours, 6.00 hours, 8.00 hours, 12.00 hours, 
16.00 hours, and 24.00 hours after dosing. Blood samples 
were collected in tubes containing heparin and centrifuged to 
separate the plasma fraction of the blood. The resulting plasma 
was immediately stored at 70nC and analyzed by liquid 
chromatography tandem mass spectrometry (LC-MS/MS). 
Four hours after drug administration, a standard lunch meal 
containing soup (no carrots), a half chicken, rice with mixed 
vegetables (no carrots), yogurt, a loaf of bread, and salad 
(tomato and cucumber) was served, and subjects had free 
access to water 1 hour after drug administration.
Chemicals and reagents
MT working standard was supplied by Morepen Laboratories 
Ltd. (Himachal Pradesh, India), while the MT-d6 internal 
standard (ISTd) was supplied by TRC (North York, Canada). 
High-performance liquid chromatography-grade methanol 
and acetonitrile were purchased from ROMIL (Cambridge, 
UK), isopropanol was obtained from Carbon Group (Cork, 
Ireland), extra pure formic acid was obtained from Scharlau 
(Port Adelaide, Australia), diethylether was obtained from 
JHD (Guangzhou, People’s Republic of China), and high-
performance liquid chromatography-grade water was sup-
plied by Sartorius Purified Water (Goettingen, Germany). 
Control human plasma was harvested from donors.
Tested brand and formulated tablets
The generic tablets, Broncast® chewable tablets (5 mg/tablet), 
were obtained from Avalon Pharma (Middle East Pharmaceu-
tical Industries Co. Ltd., Riyadh, KSA), batch number 303111. 
Singulair® pediatric chewable tablets (5 mg/tablet) were 
obtained from Merck Sharp & Dohme Ltd. (Northumberland, 
UK) and had a batch number 322559.
Instruments and chromatographic 
separations
An Agilent1200 LC system (Agilent Technologies, Santa 
Clara, CA, USA) interfaced with an API 4000 tandem MS 
system (AB Sciex, Framingham, MA, USA) was used in the 
analysis. The mass spectrometer was operated with a source 
temperature of 550nC. Electrospray in positive ionization 
mode with a needle voltage of 4 kV was used. Multiple 
reaction monitoring mode was used for the detection of 
the drug and its ISTd with monitoring of following transi-
tions: 586.384/568.300 and 586.384/422.200 for MT and 
592.288/574.300 and 592.288/427.300 for MT-d6.
An ACE 5 CN column was used with 5 cm length and 
4.6 mm internal diameter (Hichrom Limited, Reading, UK). The 
mobile phase was composed of acetonitrile and 0.005 M ammo-
nium acetate and formic acid in a ratio of 80:20:0.1 (v/v/v), 
respectively. The pH of the mobile phase was 4.30o 0.2. The 
injection volume was 10 ML, and the flow rate was 0.80 mL/min. 
The retention time for the drug and IS was 0.95 minutes.
Preparation of standard and working 
solutions
A drug solution was prepared by dissolving 0.08 g MT 
(99.4%) in methanol. The stock solution was diluted in a 
serial dilution using methanol to produce a final standard 
solution of 10.00 mL containing 76.22 Mg/mL MT.
The stock solution for the internal solution was prepared 
by weighing 0.001 g, and the volume was made up to 100 mL 
with methanol. The IS stock solution was diluted in a serial 
dilution using methanol to produce a final standard solution 
of 10.00 mL containing 0.518 Mg/mL.
The working solutions for calibration, quality control 
(QC), and IS were prepared by diluting the stock solutions 
50 times. All the calibration and the QC samples were spiked 
with IS in which 0.1 mL of plasma was spiked by 30 ML of 
the stock internal solution to get final concentration of IS of 
119.5 ng/mL; each sample was shaken for 30 seconds using 
a vortex shaker. Then 1 mL of acetonitrile was added to 
remove protein followed by vortex mixing and centrifuging 
at 14,000 rpm for 5 minutes. The supernatant was removed 
for analysis.
Validation procedures
The method was validated for its application to the analysis 
of MT in the biological fluids by spiking standards into blank 
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plasma. Sampling lasted 24 hours after drug administration 
in order to finalize the BE study. The method was validated 
in accordance with the international guidelines, and all 
the validation parameters, including linearity, accuracy, 
precision, and limit of quantitation, were calculated for the 
developed method.
The linearity assessment was performed using a series of 
nine standard plasma solutions previously spiked with MT 
(calibrator), which were employed for constructing calibration 
curves covering a concentration ranging from 6.098 ng/mL to 
365.855 ng/mL. The accuracy and precision were determined 
by using a minimum of six replicates per concentration level. 
The limit of quantitation was determined by injecting a series 
of diluted solutions with known concentrations.
In addition, stock solution stability in mobile phase was 
assessed using two standard mixtures that were equivalent 
to the lower limit of quantification and upper limit of quan-
tification along with the IS.
Short- and long-term matrix-based stabilities were assessed 
using two QCL and QCH MT concentrations. Stability after 
freeze and thaw cycles was assessed using two sets of QC 
samples that were subjected to three freeze-thaw cycles (stabil-
ity samples). The stability of the samples was compared to a 
freshly prepared calibration curve and was analyzed in a single 
run in comparison with the QC sample (comparison sample).
Whole blood stability was assessed by spiking whole 
blood samples with two different concentrations. The matrix 
effect was investigated for MT and the IS. The matrix factor 
(MF) should be calculated in each lot of matrix, by calculat-
ing the ratio of the peak area in the presence of matrix to the 
peak area in the absence of matrix (pure solution of the MT). 
The IS-normalized MF was also calculated by dividing the 
MF of the analyte by the MF of the IS. The QC samples were 
used to evaluate the performance of the assay. They were 
prepared by spiking blank plasma with MT. The QC samples 
were prepared to have low, medium, and high concentrations 
(MT: 18.293 ng/mL, 304.879 ng/mL, and 457.319 ng/mL). 
Four QC samples were incorporated with each analysis 
run as unknown samples. The concentration in each QC 
sample was determined from the calibration curve and was 
compared with the nominal concentration. The analysis run 
was accepted if at least three out of four QC samples were 
within 15% of the nominal concentration. No carryover or 
matrix effect was found.
Pharmacokinetic and statistical analysis
The PK parameters were estimated using standard non- 
compartmental methods. The peak plasma concentration 
(C
max
) and the corresponding time of peak plasma concentra-
tion (T
max
) were taken directly from the data. The elimination 
rate constant (ke) was estimated from the slope of the semi-
logarithmic plot of the terminal elimination phase of the 
plasma concentration–time curve. The equation t
1/2
 ln2/ke 
was used to calculate the elimination half-life time (T
1/2
). 
The areas under the plasma concentration–time curves for 
the drug from (AUC
0llast) and the area to infinity (AUC0linf) 
were calculated by using the linear trapezoidal method. 
Extrapolation to the infinity was achieved by dividing the last 
measurable plasma concentration C
last
 by terminal rate con-
stant k
e
. AUC
0linf is obtained from the sum of the estimated 
and extrapolated parts (AUC
0linf  AUC0llast  AUClastlinf). 
For the purpose of BE analysis, one-way analysis of vari-
ance was used to assess the effect of formulations, periods, 
sequences, and subjects on AUC
0llast, AUC0linf, and Cmax. A 
commercially available software package (Thermo Scientific 
Kinetica, version 5.1) was used for the calculations.
Results
Results of validation procedures
The newly developed and validated LC-MS/MS method was 
found to be rapid, sensitive, reproducible, and accurate for the 
analysis of MT in plasma. The relationship between concentra-
tion and peak area ratio of MT/IS was found to be linear within 
the range 6.098–365.855 ng/mL for MT. The linear equation 
was y0.00780x0.003 with a correlation (R2) of 0.9975 dur-
ing the course of the validation. The method was found to be 
sensitive with lower limit of quantification of 6.098 ng/mL. 
Mean recovery was 109.45%, 104.55%, and 101.88% for 
QCL, QCM, and QCH, respectively. The method was found 
to be precise and accurate for samples up to 1,829 ng/mL. 
Short-term stability testing of MT in plasma proved that the 
drug was stable for up to 24 hours at room temperature (RT). 
Stock solution short-term stability proved that the drug was 
stable up to 10 hours at RT. A post-preparative stability study 
showed that the drug was stable for up to 95 hours at RT in 
the autosampler. The whole blood stability study proved that 
the drug was stable for 1 hour when left in ice.
Results of PK study
Both MT 5 mg chewable tablets, Broncast and Singulair®, 
were well tolerated by all the subjects, and they were 
discharged in good health. Figure 2 shows the plasma con-
centrations of both brands indicating that the two brands are 
superimposable.
Table 1 shows a summary of the PK parameters for the two 
products of MT 5 mg chewable tablets. The point estimates 
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(ratios of geometric mean) were 101.258%, 101.556%, and 
98.106% for AUC
0llast, AUC0linf, and Cmax, respectively. No 
statistically significant difference between the two formula-
tions was found. These PK parameter values lie within the 
FDA and EMA specified BE limit (80%–125%).21,22 Our 
results in this part of the study showed equivalent clinical effi-
cacy for the two brands. There were no serious or significant 
adverse events, with both formulations being well tolerated 
when administered as a single dose.
Discussion
According to FDA, a brand name drug is defined as a drug 
marketed under a proprietary, trademark-protected name and 
a generic drug is the same as a brand name drug with regard 
to active ingredient, dosage form, safety, strength, route of 
administration, quality, performance as assessed from the PK 
profile, and intended use and contains the same salt, ester, or 
chemical form. Generic versions of a drug can vary in shape, 
scoring configuration, packaging, and excipients. If all the 
Figure 2 Plasma montelukast geometric mean concentration (ng/mL) versus time (hr) curves and log plasma montelukast geometric mean concentration versus time (hr) 
curves following a single oral dose of 5 mg chewable tablets.
Note: Triangle represents montelukast (test) and circle represents Singulair® pediatric (reference).
Abbreviation: hr, hour.
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Table 1 Summary of calculated PK parameters
PK parameters Geometric mean Minimum Median Maximum
Test formulation: montelukast containing montelukast 5 mg chewable tablets (batch number 1303111)
C
max
 (ng/mL) 253.034 146.687 257.286 360.264
AUC
0llast (nghr/mL) 1,449.910 713.579 1,522.708 2,735.068
AUC
0linf (nghr/mL) 1,516.558 776.492 1,590.272 2,885.412
T
max
 (hr) 2.36 1.50 2.50 3.25
t
1/2
 (hr) 3.84 2.11 3.89 6.62
MRT
inf
 (hr) 6.34 4.03 6.35 9.35
Residual area (%) 4.067 2.205 3.570 10.093
Reference formulation: Singulair® pediatric containing montelukast 5 mg chewable tablets (batch number 322559)
C
max
 (ng/mL) 257.920 133.041 261.842 409.845
AUC
0llast (nghr/mL) 1,431.903 702.402 1,328.291 2,652.547
AUC
0linf (nghr/mL) 1,493.326 731.565 1,390.724 2,747.167
T
max
 (hr) 2.48 1.50 2.38 5.00
t
1/2
 (hr) 3.75 2.77 3.61 6.15
MRT
inf
 (hr) 6.24 4.63 6.03 10.44
Residual area (%) 3.895 2.012 3.837 8.563
Abbreviations: PK, pharmacokinetic; AUC, area under the curve; C
max
, peak plasma concentration; T
max
, time of peak plasma concentration; t
1/2
, elimination half-life time; 
hr, hour; MRT, mean residence time.
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previous criteria are met, then the two drugs are considered 
to be therapeutically equivalent.23
During the development phase of an oral solid dosage 
form, several preformulation and formulation trials and 
tests are carried out to achieve a generic product that can be 
interchangeable with the original brand in terms of efficacy 
and safety. Accordingly, in vitro dissolution in different pH 
media is conducted on the generic product, and it must show 
a similar dissolution profile or overlap with the reference 
brand. In many cases, these tests cannot replace the in vivo 
tests that demonstrate the efficacy and safety of the generic 
product since it may contain different excipients that affect 
the rate of release in vivo.
Several previous studies have tested the BE of new 
generic MT tablets24 or other dosage forms as granules25 and 
disintegrating tablets.26 The aim of this study was to test the 
bioavailability of MT 50 mg tablets produced by Avalon 
Pharma versus the reference MT 5 mg (Singulair® pediatric) 
produced by Merck Sharp & Dohme Ltd. The two dosage 
forms were administered to 32 fasting male volunteers in 
order to eliminate the influence of food on drug absorption.
This developed and validated analytical method has many 
advantages over the existing analytical methods of MT in 
the biological system. Our method used MS/MS detector 
compared to other studies that used only fluorescent and UV 
detectors in their analysis.15,27 Moreover, this method was 
validated, while other existing methods were not.28 However, 
some analytical methods were validated for quantification 
of MT in combination with other drugs, such as gliclazide, 
nifedipine, and fexofenadine, in the human plasma but were 
not applied in any BE study.29,30
An LC-MS method validated as described earlier was 
utilized for quantification of MT 5 mg chewable tablets. 
Analysis was successfully applied without interference from 
the excipients used in the tablet formulation. The method 
provided the appropriate accuracy, sensitivity, linearity, 
precision, repeatability, and selectivity with high-sample 
throughput being economically convenient procedure for the 
support of PK studies. In fact, all validation parameters were 
conducted according to the international guidelines, and they 
were within the accepted limits as reported in Table 1.
Regarding the efficacy of our generic product, statistical 
comparison of the main PK parameters, AUC
0llast, AUC0linf , 
C
max
, and T
max
, clearly indicated no significant difference 
between test and reference tablets. The values obtained were 
compliant with the FDA and EMEA requirements for BE of 
generic drugs since the AUC
0linf, AUC0llast, and Cmax mean 
ratios are within the 80%–125% interval.31,32
The limitations of the study as per all BE studies were the 
relatively small sample size and administration of a single 
dose in healthy male volunteers. Also the inclusion of adults 
instead of pediatric volunteers could be reported as another 
limitation, but this was according to FDA guidelines and in 
order to safeguard the pediatric population from unnecessary 
risk. Several clinical studies have highlighted the efficacy of 
Singulair® pediatric in the treatment of asthma in both adults 
and children3–7 and for the symptomatic relief of allergic 
rhinitis.9–11 Given the BE demonstrated for Broncast 5 mg 
chewable tablets, this product is expected to be equally effi-
cacious and well tolerated.
Safety is also important. In our study, the administered 
drugs were tolerated and all the participated volunteers com-
pleted the study without showing any signs of adverse effects 
and were released in good health. Accordingly, this product 
offers an efficacious treatment option for individuals with 
asthma or seasonal/perennial allergic rhinitis with relatively 
lower cost in comparison with the established brand.
Conclusion
The statistical analysis of the results was performed on 
AUC
0llast, AUC0linf, and Cmax using the analysis of variance 
method and showed that both test chewable and reference 
tablets (Singulair® pediatric 5 mg chewable tablet) were 
bioequivalent, since they deliver equivalent quantities of 
active ingredient to the systemic circulation at equivalent 
rates for both AUC
0llast and Cmax ratios within the 80%–125% 
interval proposed by the FDA and EMA. These results 
showed that the formulation of this new generic tablet was 
good, which is important for achieving good therapeutic 
benefits and avoiding any potential problems that may arise 
from poor formulation.
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